I

Intuitive Surgical

Builds robots for minimally invasive surgery

Manager NPI Procurement - Systems

Full-Time
$138.6k - $234.7k/yr+ Incentives + Equity
Expert
Bachelor's, Master's, MBA
Sunnyvale, CA, USA
In PersonPreference will be given to qualified candidates who do not reside or plan to reside in the listed states.
Operations & LogisticsSupply Chain Management

About the job

Requirements
  • A bachelor's degree in Business, Supply Chain, Engineering, Finance, or a related discipline is required.
  • At least 10 years of experience in supply chain management, strategic sourcing, or procurement within manufacturing is required.
  • Strong supplier negotiation, supplier development, and contract management skills are required.
  • Exceptional project management and cross-functional collaboration abilities are required.
  • Effective communication and the ability to influence and build relationships at all levels, including executive and supplier partners, are required.
  • High proficiency in data analysis, problem-solving, and supply chain systems and tools is required.
  • The ability to thrive in fast-paced, dynamic environments with multiple priorities is required.
Responsibilities
  • Lead and manage the New Products Supply Chain team, providing guidance, development, and performance feedback.
  • Design and implement supply chain strategies for new product introductions, ensuring alignment with business goals.
  • Coordinate closely with Product Development Engineering, Supplier Engineering, and Manufacturing teams to ensure smooth product launches.
  • Develop and monitor supply chain key performance indicators for new products and proactively address issues to achieve targets.
  • Manage risk assessment and mitigation strategies regarding supplier selection, inventory planning, and logistics for new products.
  • Drive continuous improvement initiatives to enhance supply chain efficiency and responsiveness for new products.
  • Ensure compliance with company policies, industry standards, and all relevant regulations for new product supply and distribution.
  • Communicate project timelines, risks, and mitigation actions to senior leadership and cross-functional stakeholders.
  • Manage relationships with external partners, vendors, and suppliers to support new product launches.
  • Prepare reports and analysis on supply chain performance and identify areas for improvement.
Desired Qualifications
  • Experience supporting product launches or new product introduction programs.
  • Experience in medical device, pharmaceutical, or other regulated industries.
  • An advanced degree, such as an MBA or master's degree in supply chain/operations, or equivalent.
  • An APICS/ISM or similar supply chain certification.
  • Experience with global sourcing and supplier management.
  • Working knowledge of regulatory compliance, including FDA and ISO requirements, in medical device or pharmaceutical industries.

About the company

Intuitive Surgical makes da Vinci robots that let surgeons operate through a few small incisions, and Ion, a robot that reaches deep into the lungs to take tissue samples. In 2000, da Vinci became the first robotic system cleared by the FDA for general laparoscopic surgery, meaning keyhole operations in the abdomen. A surgeon sits at a nearby console and steers robotic arms holding a 3D camera and wristed instruments, which turn hand movements into smaller, steadier motions. Hospitals buy or lease the robots, then keep paying for the instruments used in each operation and for service. Intuitive was founded in 1995 to commercialize robotic surgery research from SRI International and is based in Sunnyvale, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Sunnyvale, California

Founded

1995

Get referred to Intuitive Surgical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Demand keeps compounding: da Vinci procedures grew 15% and revenue 19%, to $2.89 billion, in the June 2026 quarter.
  • Room to grow: Intuitive listed 748 open roles in October 2026, including 191 in engineering and 312 in Sunnyvale.
  • Repeat sales steady the business: instruments and service made 76% of revenue in the June 2026 quarter.

What critics are saying

  • Stock grants have shrunk: shares fell 27% from January to October 2026, versus 9% for rival Medtronic.
  • Device giants are moving in: the FDA cleared rival robots from Medtronic in December 2025 and J&J in July 2026.
  • Instrument sales face a court fight: in August 2026, an appeals court revived a repair firm's monopoly suit against Intuitive.

What makes Intuitive Surgical unique

  • Hospitals rent more than they buy: 254 of 468 da Vinci systems placed in the June 2026 quarter were leases.
  • It runs without borrowing: Intuitive had no debt and $8.6 billion in cash and investments in June 2026.
  • Its CEO is a 30-year insider: Dave Rosa, CEO since July 2025, joined as employee number nine in 1996.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Oct 1st, 2026
Intuitive Surgical down 30% in 2026, but Wall Street analysts stay bullish

Intuitive Surgical has lost nearly 30% year-to-date in 2026, making it one of healthcare's biggest losers. The stock fell over 40% by late July. Despite this decline, Wall Street remains bullish—24 of 32 analysts surveyed by S&P Global in September rated it a "buy" or "strong buy." The medical device maker faces several challenges. Growth is slowing whilst the stock trades at a forward price-to-earnings multiple over 33. Competition in China remains difficult, and the company now battles healthcare giants Johnson & Johnson, Medtronic, and Stryker in robotic surgical systems. The expiration of Affordable Care Act subsidies and rising GLP-1 drug usage have also impacted procedure volumes. However, the company's Asian revenue still jumped 20% year-over-year in Q2, suggesting these headwinds aren't insurmountable.

Yahoo Finance
Sep 17th, 2026
Intuitive Surgical, IonQ, and Accenture hold billions in net cash for growth

Investors seeking financial stability often look to companies with more cash than debt, as these businesses have greater flexibility for growth investments, buybacks, and dividends. Intuitive Surgical holds $5.22 billion in net cash. The robotic surgery pioneer achieved 20.7% annual revenue growth over the past two years, whilst its earnings per share increased 17.4% annually over five years. IonQ maintains $2.06 billion in net cash, representing 14.1% of its market capitalisation. The quantum computing company posted 181% annual revenue growth over two years and expects 163% growth next year. Accenture has $1.78 billion in net cash. The professional services firm employs approximately 774,000 people across more than 120 countries. Companies with strong balance sheets can navigate uncertain markets whilst pursuing expansion opportunities without the burden of significant debt obligations.

Yahoo Finance
Aug 23rd, 2026
Thermo Fisher vs Intuitive Surgical: which premium healthcare stock justifies valuation?

Thermo Fisher and Intuitive Surgical both delivered strong recent quarters, but their premium valuations rest on different foundations. Thermo Fisher's case depends on recovery in life sciences spending after the pandemic slowdown. The company's Life Sciences Solutions segment saw reported revenue climb 13% year-over-year, with organic revenue up 3%. The Analytical Instruments business returned to growth after nearly two years of weak demand, suggesting laboratory spending is normalising. Intuitive Surgical maintains its premium through business model strength. The company's non-GAAP gross profit margin reached 70.0%, whilst its non-GAAP operating margin expanded 330 basis points year-over-year to 42.1%. Recurring revenue streams constitute roughly 85% of total sales. Intuitive placed 468 da Vinci surgical units in fiscal Q2, marking 18% year-over-year growth, indicating continued hospital investment in robotic surgery platforms.

Yahoo Finance
Aug 19th, 2026
Abbott beats Q2 estimates with 13% sales growth as diagnostics surge 42%, while Intuitive Surgical posts 19% revenue rise

Abbott Laboratories reported strong fiscal Q2 2026 results, with sales rising 13% on a reported basis and 4.8% on a comparable basis, beating estimates and prompting the company to raise its annual profit forecast. The diagnostics segment was particularly strong, growing 42% to $3.09 billion, driven by its cancer diagnostics business following the Exact Sciences acquisition. Intuitive Surgical also exceeded expectations in Q2 2026, with revenue growing 19% to $2.89 billion and adjusted EPS of $2.80, beating forecasts by $0.30. The company placed 468 da Vinci units during the quarter, an 18% year-over-year increase, whilst maintaining a non-GAAP gross margin of 70.0%. The companies present contrasting investment cases: Abbott offers diversified healthcare portfolio resilience, whilst Intuitive Surgical relies on its robotic surgery ecosystem with recurring revenue comprising approximately 85% of total sales.

PR Newswire
Aug 17th, 2026
Intuitive leases 316,000-sq-ft facility in Penang to manufacture surgical instruments, create 1,200 jobs by 2032

Intuitive, the global leader in minimally invasive care and pioneer of robotic-assisted surgery, has signed a lease agreement with Penang Development Corporation for a new manufacturing facility in Malaysia. The 316,000-square-foot site in Bandar Cassia Technology Park will produce surgical instruments and electromechanical devices for Intuitive's da Vinci surgical system. The facility is expected to begin operations in 2028 and create 1,200 highly skilled jobs by 2032. The investment reflects Intuitive's commitment to Asia Pacific, where its da Vinci systems have treated more than 2.5 million patients across 13 markets over two decades. The expansion aims to support growing demand for robotic-assisted surgery across the region and strengthen Penang's position as a MedTech manufacturing hub in Southeast Asia.